VivoSeq
Oncology

HER2-Positive Solid Tumor

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

HER2-Positive Solid Tumor is an early-stage landscape with 0 programs across 5 companies. The most active players are Pieris Pharmaceuticals, Inc., Hengrui Therapeutics, Inc., Shanghai Pharmaceuticals Holding Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

56/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pieris Pharmaceuticals, Inc.

0 programs

PreclinicalH

Hengrui Therapeutics, Inc.

0 programs

PreclinicalS

Shanghai Pharmaceuticals Holding Co., Ltd

0 programs

PreclinicalJ

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

0 programs

PreclinicalB

Bellicum Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Unknown status2 · 15%
Terminated2 · 15%
Recruiting2 · 15%
Withdrawn1 · 8%
Suspended1 · 8%

Clinical Trials

Trial Activity

13 trials

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
Recruiting·VVoronoi, Inc·Phase 1·NCT06806982·72 enrolled
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT05245058·150 enrolled
PRS-343 in HER2-Positive Solid Tumors
Completed·PPieris Pharmaceuticals, Inc.·Phase 1·NCT03330561·85 enrolled
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Completed·JJonsson Comprehensive Cancer Center·N/A·NCT00433407·12 enrolled
First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
Completed·MMolecular Partners AG·Phase 1·NCT03084926·22 enrolled
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04521179·102 enrolled
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Completed·PPieris Pharmaceuticals, Inc.·Phase 1·NCT03650348·41 enrolled
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Suspended·BBellicum Pharmaceuticals·Phase 1·NCT04650451·220 enrolled
Study of MT-5111 in HER2-positive Solid Tumors
Terminated·MMolecular Templates, Inc.·Phase 1·NCT04029922·50 enrolled
TAC T-cells for the Treatment of HER2-positive Solid Tumors
Terminated·TTriumvira Immunologics, Inc.·Phase 1/2·NCT04727151·28 enrolled
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Withdrawn·WWashington University School of Medicine·Phase 2·NCT04757090
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Unknown status·HHengrui Therapeutics, Inc.·Phase 1·NCT02500199·50 enrolled
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
Unknown status·—·Phase 2·NCT04215159·42 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)